Date:11/11/2010

ew product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Summary financial statements attached:YM BIOSCIENCES INC.
Interim Consolidated Balance Sheets
(Expressed in Canadian dollars, unless otherwise noted) September 30,  June 30, 2010 2010 (Unaudited)   Assets Current assets:   Cash and cash equivalents
$  15,095,919 $
9,460,141   Short-term deposits
25,073,158
26,184,991   Accounts receivable
,007
,184   Prepaid expenses
24,428
237,962 40,459,512
46,044,278 Property and equipment
28,855
84,775 Intangible asset
,518,7
,645,714 $
51,107,077 $
57,774,767 Liabilities and Shareholders' Equity Current liabilities:   Accounts payable
$ 693,188 $
99,277   Accrued liabilities
2,729,655
2,085,824   Deferred revenue
594,072
,523,916 4,016,915
4,309,017 Deferred revenue
2,277,27
,650,909 Shareholders' equity:   Share capital
203,522,4
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
11. Cell Biosciences to Acquire Convergent Bioscience